Eli Lilly (LLY)
(Delayed Data from NYSE)
$806.14 USD
-12.79 (-1.56%)
Updated Nov 4, 2024 04:00 PM ET
Pre-Market: $803.24 -2.90 (-0.36%) 9:12 AM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$806.14 USD
-12.79 (-1.56%)
Updated Nov 4, 2024 04:00 PM ET
Pre-Market: $803.24 -2.90 (-0.36%) 9:12 AM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
M&A Activities Intensify in Pharma Industry
by Zacks Equity Research
M&A Activities Intensify in Pharma Industry.
No Econ Data, but Big Biopharma News
by Mark Vickery
Merck, Gilead and Lilly make progress on an otherwise slow news day.
Satsuma Plunges on Disappointing Data on Migraine Treatment
by Zacks Equity Research
Satsuma (STSA) tanks as late-stage study of STS101 (dihydroergotamine [DHE] nasal) powder as an acute treatment for migraine disappoints.
3 Safe Blue Chip Stocks to Buy as Market Bounces Back After Tech Selloff
by Benjamin Rains
There could be more selling ahead and the election might cause turbulence. Nonetheless, long-term investors might want to consider adding a few safe blue chip stocks to their portfolios...
Eli Lilly (LLY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $151.97, marking a +1.78% move from the previous day.
The Zacks Analyst Blog Highlights: DIS, NVO, BHP, AVGO and LLY
by Zacks Equity Research
The Zacks Analyst Blog Highlights: DIS, NVO, BHP, AVGO and LLY
AVEO Acquires Full Global Rights to Ficlatuzumab From Biodesix
by Zacks Equity Research
AVEO reclaims complete rights to ficlatuzumab from Biodesix for an undisclosed sum. The candidate is being developed for several cancer indications.
Top Research Reports for Disney, Novo Nordisk & BHP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Disney (DIS), Novo Nordisk (NVO) and BHP Group (BHP).
Pharma Stock Roundup: SNY, GSK, AZN's Coronavirus Vaccines/Treatments Progress
by Kinjel Shah
AstraZeneca (AZN) begins phase III study on COVID-19 vaccine candidate in the United States. Sanofi (SNY)/Glaxo's (GSK) vaccine enters clinical stage.
Lilly (LLY) Gets FDA Approval for Higher Doses of Trulicity
by Zacks Equity Research
Lilly's (LLY) higher doses of Trulicity led to superior reductions in blood glucose level and weight in type II diabetes patients compared to the currently available dose.
Eli Lilly (LLY) Stock Moves -0.35%: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $149.02, marking a -0.35% move from the previous day.
AstraZeneca's Farxiga Betters Survival in Renal Outcome Study
by Zacks Equity Research
AstraZeneca's (AZN) Farxiga significantly reduces the risk of kidney failure and cardiovascular or death in patients with chronic kidney disease.
Why Eli Lilly (LLY) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Why Is Lilly (LLY) Down 3.7% Since Last Earnings Report?
by Zacks Equity Research
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Workday (WDAY) Tops on Q2 Earnings & Revenues, Stock Rises
by Radhika Pujara
Workday's (WDAY) fiscal second-quarter results benefit from a high demand for its cloud-based HCM and financial management solutions, and synergies from the Scout RFP acquisition.
Pharma Stock Roundup: SNY, JNJ Acquisition Deals, FDA Approvals
by Kinjel Shah
J&J (JNJ) proposes to buy Momenta Pharmaceuticals while Sanofi (SNY) offers to buy Principia Biopharma
United Therapeutics Announces FDA Acceptance of Tyvaso sNDA
by Zacks Equity Research
United Therapeutics' (UTHR) INCREASE study evaluated Tyvaso in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Pharma Stock Roundup: FDA Approval for Roche's SMA Drug & Other Updates
by Kinjel Shah
Teaser: FDA approves Roche's (RHHBY) new SMA drug, Evrysdi (risdiplam).
Large-Cap Pharma Industry Outlook Dull Amid Coronavirus Woes
by Kinjel Shah
The Zacks Large-Cap Pharmaceuticals industry ranks in the bottom 26% of more than 250 Zacks industries.
Radius' (RDUS) Q2 Earnings Miss Estimates, Sales Surpass
by Zacks Equity Research
Radius (RDUS) reports a wider-than-expected loss but beats sales estimates in the second quarter.
5 Stocks in the Spotlight on Trump's Coronavirus Vaccine Optimism
by Ritujay Ghosh
Millions are pinning their hopes on a handful of drugmakers, which are into the final phases of their vaccine trial.
Pharma ETFs Soar on Robust Q2 Earnings
by Sweta Killa
Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.
Pharma Stock Roundup: ABBV, MRK Q2 Earnings & Coronavirus Updates in Focus
by Kinjel Shah
Sanofi (SNY)/Glaxo (GSK) and J&J (JNJ) sign deals with U.S. government for coronavirus vaccine candidate. Several drugmakers announce second-quarter results.
The Zacks Analyst Blog Highlights: Apple, Mastercard, Eli Lilly, PetroChina and Anheuser-Busch InBev
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Mastercard, Eli Lilly, PetroChina and Anheuser-Busch InBev